endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

R&D channel feed

Ver­tex is re­or­ga­niz­ing and con­sol­i­dat­ing R&D, shut­ter­ing a site in Cana­da

9 years ago
Pharma

Bris­tol-My­ers part­ners with Park­er In­sti­tute, CRI on a next-gen twist on trans­la­tion­al R&D

9 years ago

Pumped by an ear­ly glimpse of ef­fi­ca­cy, Newron charts a piv­otal course for schiz­o­phre­nia drug

9 years ago
Pharma

A Foamix ac­ne drug PhI­II bombs, send­ing shares in­to a tail­spin

9 years ago

Al­ler­gan scores a PhI­II win with an ac­ne drug now head­ed to the FDA

9 years ago

Eli Lil­ly un­veils an $850M makeover as Trump pounds the ta­ble for new US jobs, man­u­fac­tur­ing

9 years ago
People
Pharma

Xenon’s lead in-house drug flops in a mid-stage test and stock plunges low­er

9 years ago

Sleuthy Google up­start Cal­i­co forges a rare biotech col­lab­o­ra­tion on ag­ing with No­var­tis-backed C4

9 years ago
Pharma

Ul­tragenyx shares tum­ble low­er af­ter rare dis­ease drug fails PhII tri­al

9 years ago

Te­va de­nies big lay­offs are planned, but will push greater ef­fi­cien­cy and shut­ter floun­der­ing ef­forts

9 years ago

Stag­gered by a Duchenne pa­tient’s death, Akashi fi­nal­ly gets a green light to get back in­to the clin­ic

9 years ago
Pharma

Once scored as a po­ten­tial block­buster, No­var­tis’ sere­lax­in fiz­zles in crit­i­cal car­dio out­comes test

9 years ago

No­var­tis boasts a big new ad­van­tage for Cosen­tyx as da­ta in­di­cate the block­buster can mod­i­fy pso­ri­a­sis

9 years ago

Strug­gling Heat gets a warm re­sponse to a snap­shot on can­cer vax da­ta

9 years ago

SutroVax rais­es $64M with plans to chal­lenge Pfiz­er’s megablock­buster Pre­vnar 13 for the heavy­weight ti­tle in vac­cines

9 years ago
Financing

Ae­vi shares smashed by a tri­al fail­ure for AD­HD ge­net­ic sub­group

9 years ago

Lag­gard Lil­ly says its CDK 4/6 drug abe­maci­clib scored in PhI­II, while ri­vals at No­var­tis, Pfiz­er sharp­en their knives

9 years ago

Want to buy a pain ther­a­py? Nek­tar lays out a PhI­II sales pitch

9 years ago

Heart at­tack while on Repatha? Am­gen will give you your mon­ey back

9 years ago
Pharma

Cir­cas­sia forges a $300M COPD sales/de­vel­op­ment pact for US rights on two As­traZeneca drugs

9 years ago
Pharma

Trump’s bud­get takes a big bite out of the NIH, with big new fees for bio­phar­ma

9 years ago
People
Pharma

Cat­a­lyst shares jazzed by a new round of pos­i­tive re­sults for a rare neu­ro­mus­cu­lar dis­ease

9 years ago

Tesaro shares skid low­er as As­traZeneca wows with PhI­II da­ta on PARP drug for ovar­i­an can­cer

9 years ago

Am­gen steers PC­SK9 block­buster hope­ful through an­oth­er promis­ing PhI­II, but the crit­i­cal test is loom­ing

9 years ago
First page Previous page 304305306307308309310 Next page Last page
A service from the Financial Times